Imprimis Pharma (IMMY) Reports Q2 EPS of $0.07, Beats on Revenues

Imprimis Pharma (NASDAQ: IMMY) reported Q2 EPS of $0.07. Revenue for the quarter came in at $6.9 million versus the consensus estimate of $6.5 million.

Second Quarter 2017 and Recent Financial Highlights:

• Revenue of $6.9 million, up 40% year over year
• Net income of $1.5 million, or $0.07 per share of common stock (basic)
• Gross margin of 52%
• Adjusted EBITDA loss of $(1.9) million
• Gross ophthalmology-related revenue of $4.7 million, up over 70% year over year
• $5.7 million gain recorded related to spin-off and deconsolidation of Eton Pharmaceuticals
• In July, closed on a $16 million term loan with SWK Holdings and its partners, and retired previous $13M loan agreement

For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15